Prognostic factors associated with recurrent COVID-19 and impact of SARS-CoV-2 vaccine on patients with chronic lymphocytic leukemia.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
71 patients (33.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
High comorbidity burden and active therapy increase reinfection risk, while booster vaccination may extend protection intervals. Vaccination boosters are essential to reduce COVID-19 morbidity in this immunocompromised population.
[INTRODUCTION] Patients with chronic lymphocytic leukemia (CLL) are highly vulnerable to infections owing to persistent immune dysfunction, leading to an increased risk of severe disease and reinfecti
- 95% CI 1.17-3.16
APA
Pepe S, Mazzarella R, et al. (2025). Prognostic factors associated with recurrent COVID-19 and impact of SARS-CoV-2 vaccine on patients with chronic lymphocytic leukemia.. Frontiers in oncology, 15, 1737446. https://doi.org/10.3389/fonc.2025.1737446
MLA
Pepe S, et al.. "Prognostic factors associated with recurrent COVID-19 and impact of SARS-CoV-2 vaccine on patients with chronic lymphocytic leukemia.." Frontiers in oncology, vol. 15, 2025, pp. 1737446.
PMID
41584572 ↗
Abstract 한글 요약
[INTRODUCTION] Patients with chronic lymphocytic leukemia (CLL) are highly vulnerable to infections owing to persistent immune dysfunction, leading to an increased risk of severe disease and reinfection.
[METHODS] We conducted a retrospective study of 210 CLL patients managed at the Hematology Unit, Sapienza University of Rome, who survived an initial SARS-CoV-2 infection between March 2020 and December 2024. The aim of this study was to assess the incidence, clinical course, and predictors of subsequent COVID-19 events during the Omicron-dominant period.
[RESULTS] A subsequent COVID-19 occurred in 71 patients (33.8%), diagnosed after a median of 14 months (IQR, 9-20) from the first episode. Reinfections were significantly more frequent in patients who had experienced their first infection before the Omicron wave (47% vs. 30%; = 0.039). Compared with the initial event, subsequent COVID-19 was milder, with lower rates of pneumonia (8.4% vs. 22.7%; = 0.008), hospitalization (8.4% vs. 25.4%; = 0.002), and no COVID-19-related deaths. Patients on active CLL treatment and those with a Cumulative Illness Rating Scale score ≥6 were at significantly higher risk of reinfection. In multivariate analysis, ongoing CLL therapy (HR 1.92; 95% CI: 1.17-3.16; = 0.010) and elevated comorbidity burden (HR 2.20; 95% CI: 1.30-3.71; = 0.003) independently predicted reinfection. SARS-CoV-2 vaccination did not significantly prevent new infections (36% vs. 33%; = 0.638), but booster doses were associated with prolonged reinfection-free survival (16.3 vs. 9.3 months; = 0.001). These findings indicate that SARS-CoV-2 reinfections remain common but generally mild among CLL patients in the Omicron era. High comorbidity burden and active therapy increase reinfection risk, while booster vaccination may extend protection intervals. Vaccination boosters are essential to reduce COVID-19 morbidity in this immunocompromised population.
[METHODS] We conducted a retrospective study of 210 CLL patients managed at the Hematology Unit, Sapienza University of Rome, who survived an initial SARS-CoV-2 infection between March 2020 and December 2024. The aim of this study was to assess the incidence, clinical course, and predictors of subsequent COVID-19 events during the Omicron-dominant period.
[RESULTS] A subsequent COVID-19 occurred in 71 patients (33.8%), diagnosed after a median of 14 months (IQR, 9-20) from the first episode. Reinfections were significantly more frequent in patients who had experienced their first infection before the Omicron wave (47% vs. 30%; = 0.039). Compared with the initial event, subsequent COVID-19 was milder, with lower rates of pneumonia (8.4% vs. 22.7%; = 0.008), hospitalization (8.4% vs. 25.4%; = 0.002), and no COVID-19-related deaths. Patients on active CLL treatment and those with a Cumulative Illness Rating Scale score ≥6 were at significantly higher risk of reinfection. In multivariate analysis, ongoing CLL therapy (HR 1.92; 95% CI: 1.17-3.16; = 0.010) and elevated comorbidity burden (HR 2.20; 95% CI: 1.30-3.71; = 0.003) independently predicted reinfection. SARS-CoV-2 vaccination did not significantly prevent new infections (36% vs. 33%; = 0.638), but booster doses were associated with prolonged reinfection-free survival (16.3 vs. 9.3 months; = 0.001). These findings indicate that SARS-CoV-2 reinfections remain common but generally mild among CLL patients in the Omicron era. High comorbidity burden and active therapy increase reinfection risk, while booster vaccination may extend protection intervals. Vaccination boosters are essential to reduce COVID-19 morbidity in this immunocompromised population.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Comparative evaluation of two NGS-based assays for somatic hypermutation analysis of IGHV genes in chronic lymphocytic leukemia.
- From Time-Limited Therapy to Treatment-Free Observation: The Evolving Role of MRD in CLL Management.
- Is Brukinsa (Zanubrutinib) a Safer Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia? A Systematic Review and Meta-Analysis.
- Longitudinal Whole-Exome Sequencing Identifies Clonal Hematopoiesis and Genomic Heterogeneity as a Predictor of Treatment Outcome in Patients with Newly Diagnosed, Elderly Chronic Lymphocytic Leukemia.
- Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B-cell malignancies.
- ESE and Transfer Learning for Breast Tumor Classification.